Can Miralax Cause Hyponatremia?
Miralax (polyethylene glycol 3350) can cause hyponatremia, but this is a rare occurrence that appears to be primarily associated with contaminated products or when used as part of high-volume bowel preparation solutions, rather than standard therapeutic dosing for constipation.
Evidence from Clinical Trials
The most robust safety data comes from large-scale clinical trials and guidelines. In the pivotal 6-month randomized controlled trial of 304 patients with chronic constipation, no clinically significant changes in electrolytes, including sodium, were observed with standard-dose PEG 3350 (17g daily) 1. Similarly, a 12-month open-label safety study of 311 patients (including 117 elderly patients) found no clinically significant changes in serum electrolytes over 218 patient-years of exposure 2.
When Hyponatremia Can Occur
Bowel Preparation Formulations
A key distinction exists between:
- PEG 3350 alone (Miralax): Standard 17g daily dose for constipation
- PEG with electrolyte solutions (PEG-ELS): Used for colonoscopy preparation
- PEG 3350 plus sports drinks (PEG-SD): Hypo-osmotic preparation
A randomized trial comparing these preparations found that while hyponatremia occurred in 3.9% with PEG-SD versus 2.2% with PEG-ELS, this difference was not statistically significant 3. Importantly, electrolyte changes were small but significantly worse with PEG-SD for sodium, potassium, and chloride.
Rare Case Reports
Iso-osmolar hyponatremia from oral PEG absorption has been documented in case reports, demonstrating that systemic absorption can occur in the gastrointestinal tract 4. Additionally, one case report described potential ethylene glycol contamination of generic PEG 3350 leading to metabolic complications 5, though this represents product contamination rather than an inherent property of properly manufactured PEG 3350.
Clinical Implications and Risk Stratification
Low-Risk Patients
For standard therapeutic use (17g daily for constipation):
- Hyponatremia risk is minimal with properly manufactured PEG 3350
- No routine electrolyte monitoring needed for short-term use
- The 2023 AGA/ACG guidelines recommend PEG as first-line therapy without specific warnings about hyponatremia 1
Higher-Risk Scenarios
Monitor electrolytes in patients with:
- High-volume bowel preparation regimens (especially PEG-SD formulations)
- Baseline electrolyte abnormalities
- Renal insufficiency
- Elderly patients on diuretics or other medications affecting sodium balance
- Prolonged high-dose use beyond standard recommendations
Pediatric Considerations
A retrospective cohort of 13,235 children under 2 years found only 2.0% had signs/symptoms potentially associated with electrolyte disturbance, and none had abnormal electrolyte values 6, suggesting the risk is low even in vulnerable populations.
Common Pitfalls to Avoid
- Don't confuse standard-dose PEG 3350 with high-volume bowel prep formulations - the latter carry higher electrolyte disturbance risk
- Be aware of generic product quality - rare contamination cases have been reported 5
- Don't routinely check electrolytes for standard constipation treatment unless patient has risk factors
- Recognize that diarrhea (occurring in ~3% of patients) can indirectly affect electrolytes through fluid losses 1
Bottom Line
While hyponatremia is theoretically possible with Miralax, the actual clinical risk at standard therapeutic doses (17g daily) is extremely low based on extensive safety data. The documented adverse effects are primarily gastrointestinal (diarrhea, bloating, flatulence, nausea) rather than electrolyte disturbances 1, 2. Hyponatremia concerns are more relevant for high-volume bowel preparation regimens or in patients with specific risk factors warranting electrolyte monitoring.